ArticleEpidemiology and infection2025
Risk factors and diagnostic indicators for congenital syphilis: a Nationwide retrospective survey.
Article in Epidemiology and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This nationwide retrospective study in Japan aimed to identify risk factors and diagnostic indicators for congenital syphilis (CS) and improve diagnostic accuracy. Data were collected from 230 pregnant women diagnosed with syphilis and their infants between 2015 and 2024. Of these, 49 infants were diagnosed with definite or highly probable CS, while 73 infants with excluded CS served as the control group. Multivariable logistic regression analysis revealed two significant risk factors for CS: maternal treatment not completed more than 4 weeks before delivery (odds ratio [OR]: 7.20; 95% confidence interval [CI]: 1.38-37.56; p = 0.02) and elevated total IgM levels in the infant (>20 mg/dL) (OR: 65.31; 95% CI: 4.53-941.39; p = 0.002). When using infant rapid plasma reagin (RPR) ≥1 as a diagnostic indicator, sensitivity was 93.8% (n = 48). In contrast, the infant-to-mother RPR ratio ≥1 showed a lower sensitivity of 34.3%, with fewer cases available for analysis (n = 35) due to limited maternal data. These findings indicate that delayed maternal treatment and high total IgM levels in the infant are significant risk factors, while the infant's RPR titre serves as a useful diagnostic indicator for CS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.